Zobrazeno 1 - 10
of 214
pro vyhledávání: '"Jeffrey A, Borgia"'
Autor:
Philip Bonomi, Hita Moudgalya, Sandra L. Gomez, Palmi Shah, Sanjib Basu, Marta Batus, Levi B. Martinka, Ahmed Abdelkader, Iphigenia Tzameli, Sonia Cobain, Susie Collins, Edmund J. Keliher, Danna M. Breen, Roberto A. Calle, Mary Jo Fidler, Jeffrey A. Borgia
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 15, Iss 6, Pp 2311-2322 (2024)
Abstract Background The primary objective of this study was to assess the frequency of body composition increases and their relationships to changes in body weight in two cohorts of real world, treatment‐naïve, advanced non‐small cell lung cance
Externí odkaz:
https://doaj.org/article/9783cab46df946fea677b29c1671a54e
Autor:
Shaoqiu Chen, Fangfang Liu, Yuanyuan Fu, Chris K. Deng, Jeffrey A. Borgia, Abdul-Ghani Ayman, Masaki Nasu, Mayumi Jijiwa, Hua Yang, Ting Gong, Junlong Wang, Zhougui Ling, Xiaoyan Wang, Hongwei Wang, Qian Chu, Youping Deng
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-5 (2024)
Abstract Background Immune checkpoint inhibitors (ICIs) have revolutionized the treatment landscape for non-small cell lung cancer (NSCLC). The variability in patient responses necessitates a blood-based, multi-cohort gene signature to predict ICI re
Externí odkaz:
https://doaj.org/article/91bd677c82d3492abc8d495bd1435c09
Autor:
Talib Chaudhry, MD, Vaishnavi Krishnan, MD, Andrew E. Donaldson, MD, Zachary M. Palmisano, BS, Sanjib Basu, PhD, Nicole M. Geissen, DO, Justin M. Karush, MD, Gillian C. Alex, MD, Jeffrey A. Borgia, PhD, Michael J. Liptay, MD, Christopher W. Seder, MD
Publikováno v:
JTCVS Open, Vol 16, Iss , Pp 948-959 (2023)
Background: Conditional survival (CS) analyses provide an estimate of survival accounting for years already survived after treatment. We aim to evaluate the difference between actuarial and conditional survival in patients following lung resection fo
Externí odkaz:
https://doaj.org/article/3c57ad3278eb4dd8a83b44d6090948cf
Autor:
Kyle D Anderson, Christian Beckmann, Saskia Heermant, Frank C Ko, Bryan Dulion, Imad Tarhoni, Jeffrey A Borgia, Amarjit S Virdi, Markus A Wimmer, D Rick Sumner, Ryan D Ross
Publikováno v:
JBMR Plus, Vol 7, Iss 11, Pp n/a-n/a (2023)
ABSTRACT An increasing number of patients with type 2 diabetes (T2DM) will require total joint replacement (TJR) in the next decade. T2DM patients are at increased risk for TJR failure, but the mechanisms are not well understood. The current study us
Externí odkaz:
https://doaj.org/article/e5de1822a7364e4cb362b8e66e444812
Autor:
Ateeq M. Khaliq, Cihat Erdogan, Zeyneb Kurt, Sultan Sevgi Turgut, Miles W. Grunvald, Tim Rand, Sonal Khare, Jeffrey A. Borgia, Dana M. Hayden, Sam G. Pappas, Henry R. Govekar, Audrey E. Kam, Jochen Reiser, Kiran Turaga, Milan Radovich, Yong Zang, Yingjie Qiu, Yunlong Liu, Melissa L. Fishel, Anita Turk, Vineet Gupta, Ram Al-Sabti, Janakiraman Subramanian, Timothy M. Kuzel, Anguraj Sadanandam, Levi Waldron, Arif Hussain, Mohammad Saleem, Bassel El-Rayes, Ameen A. Salahudeen, Ashiq Masood
Publikováno v:
Genome Biology, Vol 23, Iss 1, Pp 1-30 (2022)
Abstract Background Colorectal cancer (CRC) consensus molecular subtypes (CMS) have different immunological, stromal cell, and clinicopathological characteristics. Single-cell characterization of CMS subtype tumor microenvironments is required to elu
Externí odkaz:
https://doaj.org/article/ae2d60102a98447596fa9e335944c864
Autor:
Nicholas J. Skertich, MD, Fei Chu, MD, PhD, Imad AM Tarhoni, MD, PhD, Stephen Szajek, MS, Jeffrey A. Borgia, PhD, Mary Beth Madonna, MD
Publikováno v:
Surgery Open Science, Vol 6, Iss , Pp 10-14 (2021)
Background: Inhibition of the programmed death ligand 1, programmed death 1 pathway has been successfully used for treatment of multiple advanced adult cancers. However, its use in pediatric osteosarcoma is still in its infancy. In this study, we inv
Externí odkaz:
https://doaj.org/article/d0d96fadea01498a9d7fba6667923e85
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 8 (2022)
BackgroundPlasma cardiac biomarkers have emerged as a cost-effective diagnostic tool aimed at early identification of cardiotoxicity. Soluble urokinase plasminogen activator receptor (suPAR) is a bone marrow cell derived signaling molecule that is as
Externí odkaz:
https://doaj.org/article/6cada3497bd44614b359a128740c4d17
Autor:
Brian M. Larsen, Madhavi Kannan, Lee F. Langer, Benjamin D. Leibowitz, Aicha Bentaieb, Andrea Cancino, Igor Dolgalev, Bridgette E. Drummond, Jonathan R. Dry, Chi-Sing Ho, Gaurav Khullar, Benjamin A. Krantz, Brandon Mapes, Kelly E. McKinnon, Jessica Metti, Jason F. Perera, Tim A. Rand, Veronica Sanchez-Freire, Jenna M. Shaxted, Michelle M. Stein, Michael A. Streit, Yi-Hung Carol Tan, Yilin Zhang, Ende Zhao, Jagadish Venkataraman, Martin C. Stumpe, Jeffrey A. Borgia, Ashiq Masood, Daniel V.T. Catenacci, Jeremy V. Mathews, Demirkan B. Gursel, Jian-Jun Wei, Theodore H. Welling, Diane M. Simeone, Kevin P. White, Aly A. Khan, Catherine Igartua, Ameen A. Salahudeen
Publikováno v:
Cell Reports, Vol 36, Iss 4, Pp 109429- (2021)
Summary: Patient-derived tumor organoids (TOs) are emerging as high-fidelity models to study cancer biology and develop novel precision medicine therapeutics. However, utilizing TOs for systems-biology-based approaches has been limited by a lack of s
Externí odkaz:
https://doaj.org/article/9e05120e2cf8481abf4978520140395c
Autor:
Yuhong Dou, Yong Zhu, Junmei Ai, Hankui Chen, Helu Liu, Jeffrey A. Borgia, Xiao Li, Fan Yang, Bin Jiang, Jun Wang, Youping Deng
Publikováno v:
BMC Genomics, Vol 19, Iss 1, Pp 1-10 (2018)
Abstract Background Lung cancer is a major cause of cancer-related mortality worldwide, and around two-thirds of patients have metastasis at diagnosis. Thus, detecting lung cancer at an early stage could reduce mortality. Aberrant levels of circulati
Externí odkaz:
https://doaj.org/article/d2ba930125ce4484b36956df2d6c66e7
Autor:
Mary Jo Fidler, Cristina L. Fhied, Joanna Roder, Sanjib Basu, Selina Sayidine, Ibtihaj Fughhi, Mark Pool, Marta Batus, Philip Bonomi, Jeffrey A. Borgia
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-9 (2018)
Abstract Background The VeriStrat test is a serum proteomic signature originally discovered in non-responders to second line gefitinib treatment and subsequently used to predict differential benefit from erlotinib versus chemotherapy in previously tr
Externí odkaz:
https://doaj.org/article/50ebd1b8392c48aa9f668f55a3ffc1c6